Drug Trial Radar · NCT07879170
A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Aug 5, 2026
Primary completion
Dec 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- EpygenixIndustry
- Sponsor type
- Industry
- Collaborators
- Harmony Biosciences Management, Inc.
- First posted
- Oct 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to evaluate the safety and tolerability of single and multiple ascending doses of EPX-100 in healthy adult participants.
Conditions
- Healthy Participants
Interventions
EPX-100Drug
Oral solution
EPX-100-Matching PlaceboDrug
Oral Solution
MoxifloxacinDrug
Over-encapsulated tablet
Moxifloxacin-Matching PlaceboDrug
Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) in Part 1 SADTime frame: Part 1 SAD: up to Day 18
- Number of Participants with TEAEs in Part 2 MADTime frame: Part 2 MAD: up to Day 31
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.